We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
The current 0RAD market cap is 80.6M. The company's latest EPS is EUR -1.1759 and P/E is -4.70.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 25.95M | 10.43M | 26.31M | 18.3M | 2.23M |
| Operating Income | -1.47M | -18.99M | -16.6M | -18.4M | -22.99M |
| Net Income | -4.65M | -16.56M | -16.85M | -17.76M | -23M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 88.93M | 96.97M | 101.88M | 91.78M | 82.05M |
| Total Liabilities | 30.4M | 35.61M | 53.99M | 59.12M | 59.08M |
| Total Equity | 58.54M | 61.36M | 47.89M | 32.66M | 22.98M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 9.14M | -19.28M | -9.92M | -18.25M | -19.76M |
| Investing | 2.38M | -504k | -827k | 26k | -507k |
| Financing | 4.76M | 23.31M | 14.96M | 10.27M | 13.32M |
| Market Cap | 80.6M |
| Price to Earnings Ratio | -4.70 |
| Price to Sales Ratio | 48.59 |
| Price to Cash Ratio | 5.79 |
| Price to Book Ratio | 4.71 |
| Dividend Yield | - |
| Shares Outstanding | 19.56M |
| Average Volume (1 week) | 329 |
| Average Volume (1 Month) | 403 |
| 52 Week Change | 0.00% |
| 52 Week High | 4.12 |
| 52 Week Low | 4.12 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Ose Immunotherapeutics Sa |
| Address |
22 boulevard de benoni goullin nantes, loire-atlantique 44200 |
| Website | https://www.ose-immuno.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
